目的探究血清microRNA-21(miR-21)、microRNA-193a-3p(miR-193a-3p)水平与结直肠癌患者手术预后的关系。方法回顾性分析2020年1月—2022年1月苏州大学附属第一医院收治112例结直肠癌患者的病历资料。患者均接受结直肠癌根治术,术后随访1...目的探究血清microRNA-21(miR-21)、microRNA-193a-3p(miR-193a-3p)水平与结直肠癌患者手术预后的关系。方法回顾性分析2020年1月—2022年1月苏州大学附属第一医院收治112例结直肠癌患者的病历资料。患者均接受结直肠癌根治术,术后随访16个月,记录患者的预后生存结局,多因素逐步Logistic回归分析结直肠癌患者手术预后的影响因素,评估血清miR-21、miR-193a-3p对结直肠癌患者预后的预测效能。结果112例结直肠癌患者死亡22例,病死率为19.64%;生存90例,生存率为80.36%。死亡组术前血清miR-21 mRNA相对表达量、临床分期Ⅲ期占比、淋巴结转移率均高于生存组(P<0.05),血清miR-193a-3p m RNA相对表达量低于生存组(P<0.05)。多因素逐步Logistic回归分析结果显示,临床分期Ⅲ期[OR=3.777(95%CI:1.399,10.194)]、淋巴结转移[OR=5.099(95%CI:1.715,15.156)]、miR-21表达升高[OR=4.889(95%CI:1.645,14.533)]、miR-193a-3p表达降低[OR=4.402(95%CI:1.481,13.084)]均是直肠癌患者预后的影响因素(P<0.05)。受试者工作特性曲线分析结果显示,血清miR-21、miR-193a-3p单一及联合预测结直肠癌预后的敏感性分别为69.04%(95%CI:0.487,0.813)、72.73%(95%CI:0.495,0.884)、86.36%(95%CI:0.640,0.964),特异性分别为62.22%(95%CI:0.513,0.720)、68.89%(95%CI:0.581,0.780)、90.00%(95%CI:0.814,0.950),曲线下面积分别为0.782、0.731和0.901。结论结直肠癌患者术前miR-21、miR-193a-3p表达与术后预后密切相关,且在结直肠癌患者的预后结局中表现出良好的预测效能。展开更多
本研究旨在深度剖析长链非编码RNA P53和P21在大鼠动脉粥样硬化模型中的作用及应用潜能。择取60只大鼠,随机平均划分为正常组与粥样硬化组,借由构建大鼠动脉粥样硬化模型,综合运用多种实验技术(如免疫组织化学染色、实时荧光定量PCR、...本研究旨在深度剖析长链非编码RNA P53和P21在大鼠动脉粥样硬化模型中的作用及应用潜能。择取60只大鼠,随机平均划分为正常组与粥样硬化组,借由构建大鼠动脉粥样硬化模型,综合运用多种实验技术(如免疫组织化学染色、实时荧光定量PCR、蛋白质印迹法、酶联免疫分析等)及仪器(如彩色多普勒超声诊断仪),对两组中P53和P21的表达状况、调控机制及其与疾病演进的关联予以系统性且全方位的解析。研究成果有望为动脉粥样硬化的诊断与治疗提供新颖且极具价值的靶点与策略。This study aims to deeply analyze the role and application potential of long non-coding RNA P53 and P21 in rat atherosclerosis model. 60 rats were selected and randomly divided into normal group and atherosclerosis group. By constructing rat atherosclerosis model, a variety of experimental techniques (such as immunohistochemistry staining, real-time fluorescence quantitative PCR, protein blotting, enzyme-linked immunosorbent assay, etc.) and instruments (such as color Doppler ultrasound diagnostic instrument) were used to systematically and comprehensively analyze the expression status, regulatory mechanism and relationship between P53 and P21 and disease progression in the two groups. The research results are expected to provide novel and valuable targets and strategies for the diagnosis and treatment of atherosclerosis.展开更多
文摘目的探究血清microRNA-21(miR-21)、microRNA-193a-3p(miR-193a-3p)水平与结直肠癌患者手术预后的关系。方法回顾性分析2020年1月—2022年1月苏州大学附属第一医院收治112例结直肠癌患者的病历资料。患者均接受结直肠癌根治术,术后随访16个月,记录患者的预后生存结局,多因素逐步Logistic回归分析结直肠癌患者手术预后的影响因素,评估血清miR-21、miR-193a-3p对结直肠癌患者预后的预测效能。结果112例结直肠癌患者死亡22例,病死率为19.64%;生存90例,生存率为80.36%。死亡组术前血清miR-21 mRNA相对表达量、临床分期Ⅲ期占比、淋巴结转移率均高于生存组(P<0.05),血清miR-193a-3p m RNA相对表达量低于生存组(P<0.05)。多因素逐步Logistic回归分析结果显示,临床分期Ⅲ期[OR=3.777(95%CI:1.399,10.194)]、淋巴结转移[OR=5.099(95%CI:1.715,15.156)]、miR-21表达升高[OR=4.889(95%CI:1.645,14.533)]、miR-193a-3p表达降低[OR=4.402(95%CI:1.481,13.084)]均是直肠癌患者预后的影响因素(P<0.05)。受试者工作特性曲线分析结果显示,血清miR-21、miR-193a-3p单一及联合预测结直肠癌预后的敏感性分别为69.04%(95%CI:0.487,0.813)、72.73%(95%CI:0.495,0.884)、86.36%(95%CI:0.640,0.964),特异性分别为62.22%(95%CI:0.513,0.720)、68.89%(95%CI:0.581,0.780)、90.00%(95%CI:0.814,0.950),曲线下面积分别为0.782、0.731和0.901。结论结直肠癌患者术前miR-21、miR-193a-3p表达与术后预后密切相关,且在结直肠癌患者的预后结局中表现出良好的预测效能。
文摘本研究旨在深度剖析长链非编码RNA P53和P21在大鼠动脉粥样硬化模型中的作用及应用潜能。择取60只大鼠,随机平均划分为正常组与粥样硬化组,借由构建大鼠动脉粥样硬化模型,综合运用多种实验技术(如免疫组织化学染色、实时荧光定量PCR、蛋白质印迹法、酶联免疫分析等)及仪器(如彩色多普勒超声诊断仪),对两组中P53和P21的表达状况、调控机制及其与疾病演进的关联予以系统性且全方位的解析。研究成果有望为动脉粥样硬化的诊断与治疗提供新颖且极具价值的靶点与策略。This study aims to deeply analyze the role and application potential of long non-coding RNA P53 and P21 in rat atherosclerosis model. 60 rats were selected and randomly divided into normal group and atherosclerosis group. By constructing rat atherosclerosis model, a variety of experimental techniques (such as immunohistochemistry staining, real-time fluorescence quantitative PCR, protein blotting, enzyme-linked immunosorbent assay, etc.) and instruments (such as color Doppler ultrasound diagnostic instrument) were used to systematically and comprehensively analyze the expression status, regulatory mechanism and relationship between P53 and P21 and disease progression in the two groups. The research results are expected to provide novel and valuable targets and strategies for the diagnosis and treatment of atherosclerosis.